These results may contribute for the development of a novel therapeutic methodology

to treat Lewis y positive cancers. Acknowledgements This work was supported by grants from The National Ridaforolimus in vivo Natural Science Foundation of China (30170980, 30571958, 30872757); item of Educational Department Science foundation of Liaoning Province (20121268) and item of Liaoning Natural Science foundation (20052107); item of Educational Department Doctor Startup Fund (20070159023); item of Educational Department Key Laboratory of Liaoning Province (2008S247); Shengjing Freedom researchers plan (200807). References 1. Kitamura K, Stockert E, Garin-Chesa P, Welt S, Llovd KO, Armour KL, Wallace TP, Harris WJ, Carr FJ, Old LJ: Specificity analysis of blood group Lewis-y Le(y) antibodies generatedagainst synthetic

and natural Le(y) determinants. Proc Natl Acad Sci USA 1994, 91: 12957–12961.CrossRefPubMed 2. Hokke CH, Neeleman AP, Koeleman Selleckchem Nutlin3a CA, Eijnden DH: Identification of an alpha3-fucosyltransferase and a novel alpha2-fucosyltransferase activity in cercariae of the schistosome Trichobilharzia ocellata: biosynthesis of the Fucalpha1 → 2Fucalpha1 → 3[Gal(NAc)beta1 → 4]GlcNAc sequence. Glycobiology 1998, 8: 393–406.CrossRefPubMed 3. Dettke M, Pálfi G, Loibner H: Activation-dependent expression of the blood group-related Lewis Y antigen on peripheral blood granulocytes. J Leukoc Biol 2000, 68: 511–514.PubMed 4. Arai Y, Nishida M: Differential diagnosis between normal endometrium and endometrial hyperplasia with immunostaining cytology using anti-LeY monoclonal antibody. Int J Gynecol Cancer 2003, 13: 42–46.CrossRefPubMed 5. Madjd Z, Parsons T, Watson NF, Spendlove I, Ellis I, Durrant LG: High expression of Lewis y/b antigens is associated with decreased survival in lymph

node negative breast carcinomas. Breast Cancer Res 2005, 7: R780-R787.CrossRefPubMed 6. Kim YS, Yuan M, Itzkowitz SH, Sun QB, Kaizu T, Palekar A, Trump BF, Hakomori S: Expression of LeY and extended LeY blood group-related antigens in human malignant, premalignant, and nonmalignant colonic tissues. Cancer Res 1986, 46: 5985–5992.PubMed 7. Yin BW, Finstad CL, Kitamura K, Federici MG, Welshinger M, Kudrvashov V, Hoskins WJ, Welt S, Lloyd KO: Serological and immunochemical analysis of Lewis y (Ley) blood group antigen expression in epithelial ovarian cancer. Sulfite dehydrogenase Int J Cancer 1996, 65: 406–412.CrossRefPubMed 8. Iwamori M, Tanaka K, Kubushiro K, Lin B, Kiguchi K, Ishiwata I, Tsukazaki K, Nozawa S: Alterations in the glyolipid composition and cellular properties of ovarian carcinoma-derived RMG-1 cells on transfection of the α1,2-fucosyltransferase gene. Cancer Sci 2005, 96: 26–30.CrossRefPubMed 9. Zhao Y, Lin B, Hao YY, Yan LM, Liu JJ, Zhu LC, Zhang SL: The effects of Lewis(y) antigen content on drug resistance to carboplatin in ovarian cancer line RMG-I. Prog Biochem Biophys 2008, 35: 1175–1182. 10.